BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Obrig TG, Karpman D. Shiga toxin pathogenesis: kidney complications and renal failure. Curr Top Microbiol Immunol 2012;357:105-36. [PMID: 21983749 DOI: 10.1007/82_2011_172] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Chromek M, Arvidsson I, Karpman D. The antimicrobial peptide cathelicidin protects mice from Escherichia coli O157: H7-mediated disease. PLoS One. 2012;7:e46476. [PMID: 23077510 DOI: 10.1371/journal.pone.0046476] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.3] [Reference Citation Analysis]
2 Fitzgerald SF, Beckett AE, Palarea-Albaladejo J, McAteer S, Shaaban S, Morgan J, Ahmad NI, Young R, Mabbott NA, Morrison L, Bono JL, Gally DL, McNeilly TN. Shiga toxin sub-type 2a increases the efficiency of Escherichia coli O157 transmission between animals and restricts epithelial regeneration in bovine enteroids. PLoS Pathog 2019;15:e1008003. [PMID: 31581229 DOI: 10.1371/journal.ppat.1008003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
3 Legros N, Dusny S, Humpf HU, Pohlentz G, Karch H, Müthing J. Shiga toxin glycosphingolipid receptors and their lipid membrane ensemble in primary human blood-brain barrier endothelial cells. Glycobiology 2017;27:99-109. [PMID: 27558838 DOI: 10.1093/glycob/cww090] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
4 Amaral MM, Sacerdoti F, Jancic C, Repetto HA, Paton AW, Paton JC, Ibarra C. Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells. PLoS One 2013;8:e70431. [PMID: 23936204 DOI: 10.1371/journal.pone.0070431] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
5 Sharma VK, Akavaram S, Bayles DO. Genomewide transcriptional response of Escherichia coli O157:H7 to norepinephrine. BMC Genomics 2022;23:107. [PMID: 35135480 DOI: 10.1186/s12864-021-08167-z] [Reference Citation Analysis]
6 Karpman D, Tati R. Complement activation in thrombotic microangiopathy. Hamostaseologie 2013;33:96-104. [PMID: 23411690 DOI: 10.5482/HAMO-12-12-0025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Liu Y, Tian S, Thaker H, Dong M. Shiga Toxins: An Update on Host Factors and Biomedical Applications. Toxins (Basel) 2021;13:222. [PMID: 33803852 DOI: 10.3390/toxins13030222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Lewis SB, Prior A, Ellis SJ, Cook V, Chan SS, Gelson W, Schüller S. Flagellin Induces β-Defensin 2 in Human Colonic Ex vivo Infection with Enterohemorrhagic Escherichia coli. Front Cell Infect Microbiol 2016;6:68. [PMID: 27446815 DOI: 10.3389/fcimb.2016.00068] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
9 Exeni RA, Fernandez-Brando RJ, Santiago AP, Fiorentino GA, Exeni AM, Ramos MV, Palermo MS. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2018;33:2057-71. [PMID: 29372302 DOI: 10.1007/s00467-017-3876-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
10 Fitzgerald SF, Lupolova N, Shaaban S, Dallman TJ, Greig D, Allison L, Tongue SC, Evans J, Henry MK, McNeilly TN, Bono JL, Gally DL. Genome structural variation in Escherichia coli O157:H7. Microb Genom 2021;7. [PMID: 34751643 DOI: 10.1099/mgen.0.000682] [Reference Citation Analysis]
11 Shimizu M. Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC‐HUS. Pediatrics International 2020;62:308-15. [DOI: 10.1111/ped.14053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
12 Gomez SA, Abrey-Recalde MJ, Panek CA, Ferrarotti NF, Repetto MG, Mejías MP, Fernández GC, Vanzulli S, Isturiz MA, Palermo MS. The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome. Clin Exp Immunol 2013;173:463-72. [PMID: 23607458 DOI: 10.1111/cei.12124] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
13 Buelli S, Zoja C, Remuzzi G, Morigi M. Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Microorganisms 2019;7:E15. [PMID: 30634669 DOI: 10.3390/microorganisms7010015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
14 Detzner J, Krojnewski E, Pohlentz G, Steil D, Humpf HU, Mellmann A, Karch H, Müthing J. Shiga Toxin (Stx)-Binding Glycosphingolipids of Primary Human Renal Cortical Epithelial Cells (pHRCEpiCs) and Stx-Mediated Cytotoxicity. Toxins (Basel) 2021;13:139. [PMID: 33673393 DOI: 10.3390/toxins13020139] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Sánchez DS, Fischer Sigel LK, Balestracci A, Ibarra C, Amaral MM, Silberstein C. Eliglustat prevents Shiga toxin 2 cytotoxic effects in human renal tubular epithelial cells. Pediatr Res 2021. [PMID: 34155339 DOI: 10.1038/s41390-021-01622-3] [Reference Citation Analysis]
16 Iversen H, L' Abée-Lund TM, Aspholm M, Arnesen LP, Lindbäck T. Commensal E. coli Stx2 lysogens produce high levels of phages after spontaneous prophage induction. Front Cell Infect Microbiol 2015;5:5. [PMID: 25692100 DOI: 10.3389/fcimb.2015.00005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
17 Loos S, Oh J, Kemper MJ. Eculizumab in STEC-HUS: need for a proper randomized controlled trial. Pediatr Nephrol 2018;33:1277-81. [PMID: 29774464 DOI: 10.1007/s00467-018-3972-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
18 Howard-Varona C, Vik DR, Solonenko NE, Li YF, Gazitua MC, Chittick L, Samiec JK, Jensen AE, Anderson P, Howard-Varona A, Kinkhabwala AA, Abedon ST, Sullivan MB. Fighting Fire with Fire: Phage Potential for the Treatment of E. coli O157 Infection. Antibiotics (Basel) 2018;7:E101. [PMID: 30453470 DOI: 10.3390/antibiotics7040101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
19 Shannon O. Platelet interaction with bacterial toxins and secreted products. Platelets 2015;26:302-8. [PMID: 25807205 DOI: 10.3109/09537104.2015.1014471] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
20 Murfin KE, Lee MM, Klassen JL, McDonald BR, Larget B, Forst S, Stock SP, Currie CR, Goodrich-Blair H. Xenorhabdus bovienii Strain Diversity Impacts Coevolution and Symbiotic Maintenance with Steinernema spp. Nematode Hosts. mBio 2015;6:e00076. [PMID: 26045536 DOI: 10.1128/mBio.00076-15] [Cited by in Crossref: 44] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
21 Warr AR, Kuehl CJ, Waldor MK. Shiga toxin remodels the intestinal epithelial transcriptional response to Enterohemorrhagic Escherichia coli. PLoS Pathog 2021;17:e1009290. [PMID: 33529199 DOI: 10.1371/journal.ppat.1009290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Patel IR, Gangiredla J, Lacher DW, Mammel MK, Jackson SA, Lampel KA, Elkins CA. FDA Escherichia coli Identification (FDA-ECID) Microarray: a Pangenome Molecular Toolbox for Serotyping, Virulence Profiling, Molecular Epidemiology, and Phylogeny. Appl Environ Microbiol 2016;82:3384-94. [PMID: 27037122 DOI: 10.1128/AEM.04077-15] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
23 Li D, Selyunin A, Mukhopadhyay S. Targeting the Early Endosome-to-Golgi Transport of Shiga Toxins as a Therapeutic Strategy. Toxins (Basel) 2020;12:E342. [PMID: 32456007 DOI: 10.3390/toxins12050342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Detzner J, Pohlentz G, Müthing J. Valid Presumption of Shiga Toxin-Mediated Damage of Developing Erythrocytes in EHEC-Associated Hemolytic Uremic Syndrome. Toxins (Basel) 2020;12:E373. [PMID: 32512916 DOI: 10.3390/toxins12060373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Murfin KE, Whooley AC, Klassen JL, Goodrich-Blair H. Comparison of Xenorhabdus bovienii bacterial strain genomes reveals diversity in symbiotic functions. BMC Genomics 2015;16:889. [PMID: 26525894 DOI: 10.1186/s12864-015-2000-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
26 Lauridsen LH, Veedu RN. Nucleic acid aptamers against biotoxins: a new paradigm toward the treatment and diagnostic approach. Nucleic Acid Ther 2012;22:371-9. [PMID: 23113767 DOI: 10.1089/nat.2012.0377] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
27 Walsh PR, Johnson S. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2019;34:1485-92. [PMID: 30058046 DOI: 10.1007/s00467-018-4025-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
28 Obata F, Obrig T. Role of Shiga/Vero toxins in pathogenesis. Microbiol Spectr 2014;2. [PMID: 25530918 DOI: 10.1128/microbiolspec.EHEC-0005-2013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
29 DesRochers TM, Kimmerling EP, Jandhyala DM, El-Jouni W, Zhou J, Thorpe CM, Leong JM, Kaplan DL. Effects of Shiga toxin type 2 on a bioengineered three-dimensional model of human renal tissue. Infect Immun 2015;83:28-38. [PMID: 25312954 DOI: 10.1128/IAI.02143-14] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
30 Chromek M. The role of the antimicrobial peptide cathelicidin in renal diseases. Pediatr Nephrol 2015;30:1225-32. [PMID: 25159719 DOI: 10.1007/s00467-014-2895-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
31 Lu Z, Liu Z, Li X, Qin X, Hong H, Zhou Z, Pieters RJ, Shi J, Wu Z. Nanobody-Based Bispecific Neutralizer for Shiga Toxin-Producing E. coli. ACS Infect Dis 2022;8:321-9. [PMID: 35015516 DOI: 10.1021/acsinfecdis.1c00456] [Reference Citation Analysis]
32 Zoja C, Buelli S, Morigi M. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. Pediatr Nephrol 2019;34:379-88. [PMID: 29214442 DOI: 10.1007/s00467-017-3850-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]